GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation

Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure 

TEMPE, Ariz., May 6, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company focused on improving the lives of patients with brain tumors, today announced Inova Fairfax Hospital as the latest GammaTile^® Center of Excellence Program designation.

The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements.   

The following physicians are now recognized with achievement:

• Mateo Ziu, MD, MBA, FAANS, Medical Director of Brain and Spine Tumor Program
• John Hamilton, MD, Neurosurgeon
• Gillian Harrison, MD, Neurosurgeon
• James Leiphart, MD, Neurosurgeon
• Mahesh Shenai, MD, Neurosurgeon
• Nilesh Vyas, MD, Neurosurgeon
• Kevin Choe, MD, PhD, Radiation Oncologist
• Daniel Kim, MD, Radiation Oncologist
• Adam Cohen, MD, Neuro-Oncologist

"Receiving this designation reinforces our dedication to putting the patient at the center, with physicians from different specialties coming together to determine the best way forward," said Dr. Mateo Ziu, Medical Director of the Brain and Spine Tumor Program at Inova Fairfax Hospital. "We're proud to offer GammaTile as an advanced treatment that can help brain tumor patients who seek care here at Inova. We will always challenge ourselves to bring the newest technology that will provide the best treatments and outcomes for our patients."

GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.¹  

About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.

About GammaTile
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.

Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com and follow @GammaTile on Facebook, Instagram, LinkedIn and X. 

Media Contact
Dawn Fallon
New Dawn Communications LLC
[email protected]
732-771-7808

References

1.     Garcia MA et al. J Neurooncol. 166:203-212 (2024).

View original content to download multimedia:https://www.prnewswire.com/news-releases/gt-medical-technologies-welcomes-new-gammatile-center-of-excellence-program-designation-302446947.html

SOURCE GT Medical Technologies